Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Other Non-Current Assets (2023 - 2025)

Silence Therapeutics' Other Non-Current Assets history spans 3 years, with the latest figure at $399000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets changed N/A year-over-year to $399000.0; the TTM value through Sep 2025 reached $399000.0, changed N/A, while the annual FY2024 figure was $3.6 million, 891.71% up from the prior year.
  • Other Non-Current Assets for Q3 2025 was $399000.0 at Silence Therapeutics, down from $3.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.9 million in Q2 2025 and bottomed at $362000.0 in Q4 2023.
  • The 3-year median for Other Non-Current Assets is $2.0 million (2024), against an average of $2.1 million.
  • The largest YoY upside for Other Non-Current Assets was 891.71% in 2024 against a maximum downside of 891.71% in 2024.
  • A 3-year view of Other Non-Current Assets shows it stood at $362000.0 in 2023, then skyrocketed by 891.71% to $3.6 million in 2024, then plummeted by 88.89% to $399000.0 in 2025.
  • Per Business Quant, the three most recent readings for SLN's Other Non-Current Assets are $399000.0 (Q3 2025), $3.9 million (Q2 2025), and $3.6 million (Q4 2024).